Switzerland is more than a point on the map in the novel: it connects Jack Harkness’s rise in the pharmaceutical industry with Jane Glasson’s past, Holly Walsh’s treatment, and the international reach of Harkness’s concealed plan. Its significance is distributed across several places rather than concentrated in one scene. Basel supplies the corporate history; Lausanne becomes a missing piece in Jane’s movements; Zürich is where Blake resumes the investigation; and Locarno is named as one of the sites of a system capable of initiating catastrophe.

Corporate Base and Harkness’s Rise

Harkness Pharmaceuticals is headquartered in Switzerland, and Basel is the city that gives this corporate connection its history. After disappearing from view between 1978 and 1981, Harkness reappears in Switzerland as personal assistant to Lenore Furgler, who has inherited control of Furgler Gesellschaft, a medium-sized pharmaceutical company based in Basel. During the 1980s, Harkness gains a place on its board and responsibility for company strategy, despite the Furgler family’s distrust of him. In 1995, as Lenore’s health declines, she sells the company to him. The account leaves the source of his purchase money uncertain, recording rumours of a loan from Vladimir Drishkov rather than establishing the story behind the financing.

Basel consequently marks a transition in Harkness’s power: he moves from working inside another family’s company to owning the business that becomes Harkness Pharmaceuticals. The location also gives the investigation a concrete geographical clue. When Blake and Don Challenor learn that the company is Swiss-based, Switzerland becomes relevant to questions that had previously seemed separate: the origins of Harkness’s fortune, Jane’s disappearance, and the source of Holly’s medicine.

Lausanne and Jane Glasson’s Unexplained Stop

Gareth Lawler recalls that he and Jane travelled through Italy by train during the Easter holiday shortly before she disappeared. On their return, Jane told him she intended to stop in Switzerland to visit a school friend, a person she had not previously mentioned. She did not invite Gareth to join this diversion. She got off the train at Lausanne while he continued home, leaving him with an abrupt separation and no explanation that would resolve its significance.

At the time, Gareth did not connect the stop with Harkness. Later, after Blake reports seeing a woman she suspects may have been Jane at Paddington, he revisits the journey: Harkness Pharmaceuticals was still headquartered in Basel, and Basel was only a couple of hours by train from Lausanne. The proximity gives his memory investigative weight, but it does not prove that Jane visited Harkness or explain whom she met. Holly Walsh emphatically rejects the suggestion that the anonymous benefactor using the name Luscinia was Jane. Switzerland therefore offers a possible route for inquiry, not a settled answer to Jane’s disappearance.

Holly Walsh’s Treatment and the Swiss Financial Trail

The Swiss connection also emerges through the treatment that has transformed Holly’s life. Don finds her online accounts describing her multiple sclerosis, her experimental drug treatment, and the help of an anonymous benefactor. At Holly’s home, Blake sees cartons of Ditrimantelline labelled as made in Switzerland and bearing the name Harkness Pharmaceuticals. The medicine is part of the ordinary domestic setting, alongside mobility aids and other products, but its label links Holly’s private care directly to the company whose affairs Don and Blake are investigating.

Holly explains that her first contact came by email from Luscinia, a name meaning nightingale. The sender claimed to work in pharmaceuticals and offered to supply Ditrimantelline anonymously, saying that disclosure could cause trouble. Holly accepted the treatment; she and her partner Anna Marchant describe its effect as transformative. The benefit to Holly is real within the account, even as the secrecy around the supply raises questions about who is paying and why.

Those questions become more specific when Holly tells Don and Blake that money from the Nightingale account at Credit Suisse has been supporting her treatment. A private investigator working for Harkness’s creditors had visited and asked about the payments, although Holly says he showed no interest in Jane. Holly worries that Luscinia may be diverting company funds and that the treatment could be cut off. The evidence establishes her concern and the investigator’s inquiry, not the identity of Luscinia or the precise origin of the money. Switzerland thus connects a patient’s dependence on an effective drug to a bank account and a corporate financial mystery, without reducing the value of her treatment to a mere clue.

Blake’s Journey to Zürich

After deciding to pursue the Swiss lead, Blake separates from Don. Don returns to Cornwall, while Blake says she will go to Switzerland with Gareth’s help and hopes the trip may also reveal something useful to Fran Revell. Their different destinations reflect a shared investigation widening across several fronts: Jane’s history, Fran’s situation, and whatever Harkness is planning. At Heathrow Airport, Don buys Blake a phone so they can remain in contact, and gives her a credit card for expenses. Blake explains that she has stayed off the grid by avoiding easy contact; the phone and card are practical signs that she is entering a new, cooperative phase of the inquiry.

The journey is Blake’s first flight. After landing at Zürich Airport, she changes money, asks the tourist office for an inexpensive but decent hotel, and takes the train into the city. The tourist office recommends Hotel Marta in Zürich, five minutes from the main railway station, at a quoted cost of two hundred francs for two nights. Its map also marks the Zurich Marriott. Blake tries to call Gareth, reaches his voicemail, leaves her number, and texts Don to say she has arrived. These small arrangements establish the immediate conditions of her investigation: she is in unfamiliar territory, equipped with money and a phone supplied by Don, but still dependent on her own efforts to make contact and find the next lead.

Locarno and the Reach of the Plan

Switzerland’s role extends beyond biography and financial tracing into the technical structure of Harkness’s scheme. Filippo Crosetti explains that he joined Jack and Astrid twelve years earlier, believing in their effort to respond to the climate crisis. Their programme used nanobots distributed through Harkness Pharmaceuticals products, including medicines, cosmetics, pesticides, and antibiotics. He describes a chain-reaction process called Cascade, designed to activate nanobots within ultrasonic range. The concealed system at Wortalleth West could initialize it, while overrides there and in Locarno were known only to Harkness and Filippo.

Locarno is therefore not described as the origin of the scheme, nor as the place where its effects begin. It is named as the location of an additional control point in a system whose reach depends on pharmaceutical products circulating far beyond Switzerland. The distinction matters: Basel represents the company’s institutional foundation, while Locarno belongs to the hidden technical infrastructure. Together with Lausanne and Zürich, these locations make Switzerland a junction between private histories, corporate power, individual care, and a transnational technological danger.

The novel’s use of Switzerland is deliberately cumulative. No single Swiss scene resolves Jane’s disappearance or identifies the Nightingale account’s backer. Instead, separate clues gather there: Harkness’s ascent in Basel, Jane’s unexplained disembarkation at Lausanne, Blake’s arrival in Zürich, and the Locarno override. The country’s narrative importance lies in how these distinct threads converge, turning geography into a map of both the investigation and the systems of influence it is uncovering.